
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc has shown a significant increase in the valuation of its partnered and wholly-owned product candidates, with the total enterprise value rising to $959 million from $627 million, reflecting strong growth prospects. The company's leading candidate, ARV-102, is now valued at $247 million, highlighting its potential in treating LRRK2-related diseases, while ARV-393 and ARV-806 have also seen notable valuation increases. The advancements in their pipeline, particularly in oncology and neurology, combined with early promising data from clinical programs, underpin a positive financial outlook for Arvinas.
Bears say
Arvinas Inc. faces a challenging financial outlook characterized by significant reductions in projected revenue for its product vepdegestrant, which has been decreased from $641.2 million to $296.9 million for 2035, indicative of unfavorable market penetration and partnership economics. The company is also experiencing difficulties in accessing capital, which jeopardizes its ability to maintain critical operations and achieve profitability in a timely manner. Additionally, the upcoming clinical trial data presents uncertainties, as unfavorable results could lead to a halt in the development of its protein degradation agents, further diminishing market potential.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares